Recently, Professor Junichiro Inoue and others at the University of Tokyo Medical Institute issued a statement stating that the drug "namonostam", which is mainly used to treat acute pancreatitis, has the effect of preventing a new type of coronavirus from entering human cells.
In other words, these drugs are expected to inhibit the proliferation of the virus in the body, and the effect will be better when used with other antiviral drugs.
Professor Junichiro Inoue and others issued a statement in 2016 that this drug may be effective against MERS (Middle East Respiratory Syndrome), and after studying a new coronavirus, which is also a coronavirus, it was found to be effective.
Nalamostat was launched in 1986 and has been sold as a major product. It is mainly used to: improve the acute symptoms of pancreatitis; systemic intravascular coagulation; and prevent blood coagulation during extracorporeal circulation in patients with bleeding lesions or bleeding tendency.
The virus infects the human body, mainly after binding to the receptor protein (ACE2 receptor) present on the cell surface, the outer membrane of the virus fuses with the cell membrane.
In the case of coronaviruses, the virus S protein binds to the ACE2 receptor on the cell membrane of human cells and is cleaved by the proteolytic enzyme TMPRSS2, and activation of the S protein indicates that the outer membrane of the virus interacts with the cell membrane.
This is important for fusion. Nalimostam significantly inhibits virus entry at concentrations as low as 1-10 nM.
Within this month, Professor Junichiro Inoue will also cooperate with the National International Medical Research Center and other institutions to apply the drug to a number of patients with new coronavirus in the form of drops and will see results as soon as possible within a few months.
Special Report: Fighting The New Coronavirus
